Skip to main content

Errata - English

PDF CSV October 5, 2022 through October 5, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
OMEPRAZOLE ORAL SUSPENSION ASSAY/Procedure USP37–NF32 4067 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Solution A: Change
with dilute phosphoric acid
to:
with dilute sodium hydroxide
POWDERED HOLY BASIL LEAF EXTRACT COMPOSITION/Content of Triterpenes USP37–NF32 5458 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm
ALCOHOL IN DEXTROSE INJECTION ASSAY/Dextrose USP37–NF32 1637 1-Jun-2014 USP38–NF33 USP38–NF33 Line 15 of Analysis: Change
A = length of the polarimeter tube (mm)
to:
A = 100 mm divided by the length of the polarimeter tube (mm)
PYRANTEL PAMOATE ASSAY/Procedure USP37–NF32 4491 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Mobile phase: Change
acetic acid
to:
glacial acetic acid
AND
Line 1 of Column efficiency: Change
NLT 8000 theoretical plates
to:
NLT 8000 theoretical plates for the pyrantel peak
CARBAMAZEPINE EXTENDED-RELEASE TABLETS ASSAY/Procedure USP37–NF32 2123 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Sample stock solution B: Change
Standard stock solution
to:
Sample stock solution A
RIBAVIRIN CAPSULES PERFORMANCE TESTS/Dissolution <711>/Procedure 1/Chromatographic system USP37–NF32 4562 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Column: Change
7-µm packing L17
to:
9-µm packing L17
DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS IMPURITIES/Limit of Ibuprofen Related Compound C USP37–NF32 2651 1-Jun-2014 USP38–NF33 USP38–NF33 Line 7 of Analysis: Change
RU = peak area ratio of ibuprofen to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
RU = peak area ratio of… Read More
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION ASSAY/Procedure USP37–NF32 4766 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Sample stock solution: Change
sulfacetamide
to:
sulfacetamide sodium
AND
Line 1 of Sample solution: Change
sulfacetamide
to:
sulfacetamide sodium
GRISEOFULVIN CAPSULES PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP37–NF32 3196 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6 of Analysis: Change
Result = (AU/AS) × (CS/CU) × P × 100
to:
Result = (AU/AS) × (CS/CU) × P × F × 100
AND… Read More
VALSARTAN ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5115 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of USP Valsartan Related Compound A RS: Change
(R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine.
AND
Line 2 of USP Valsartan Related… Read More
LAMIVUDINE AND ZIDOVUDINE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3484 1-Jun-2014 USP38–NF33 USP38–NF33 Line 12 of Analysis: Change
unidentified impurity
to:
unspecified impurity
AND
Line 19 of Analysis: Change
unidentified impurities
to:
unspecified impurities
POWDERED ECHINACEA PALLIDA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5356 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS
NYSTATIN DEFINITION USP37–NF32 4035 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6: Change
extemporaneous solution
to:
extemporaneous preparation
HOLY BASIL LEAF COMPOSITION/Content of Triterpenes USP37–NF32 5454 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm
DESCRIPTION AND SOLUBILITY Sodium Acetate USP37–NF32 1525 1-Jun-2014 USP38–NF33 USP38–NF33 Line 7: Change
transfer liquid.
to:
transfer ligand.
PROGESTERONE VAGINAL SUPPOSITORIES ASSAY/Suppositories in Fatty Acid Base USP37–NF32 4430 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of System suitability solution: Change
Transfer 2.0 mL of System suitability stock solution A and System suitability stock solution B
to:
Transfer 2.0 mL of each System suitability stock solution A and System suitability stock solution B
AND… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 First Supplement to USP37–NF32 6619 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Standard solution: Change
0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
to:
0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
AND
Line 8 of Analysis: Change
CS = concentration of ciprofloxacin in the… Read More
AMINOSALICYLATE SODIUM ASSAY/Procedure USP37–NF32 1745 1-Jun-2014 USP38–NF33 USP38–NF33 Line 15 of Analysis: Change
CU = concentration of aminosalicylate in the Sample solution (mg/mL)
to:
CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL)
QUINIDINE GLUCONATE DEFINITION USP37–NF32 4512 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6: Change
quinidine sulfate
to:
quinidine gluconate
CODEINE PHOSPHATE ORAL SOLUTION ASSAY/Procedure USP37–NF32 2451 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6 of Analysis: Change
Result = (RU/RS) × (CS/CU) × 100
to:
Result = (RU/RS) × (CS/CU) × (Mr1/Mr2 Read More
SUFENTANIL CITRATE INJECTION ASSAY/Procedure USP37–NF32 4759 1-Jun-2014 USP38–NF33 USP38–NF33 Line 11 of Analysis: Change
sufentanil
to:
sufentanil citrate
FOSPHENYTOIN SODIUM INJECTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 3096 1-Jun-2014 USP38–NF33 USP38–NF33 Before USP Fosphenytoin Sodium RS: Add
USP Endotoxin RS
TRIACETIN ASSAY/Procedure/Titrimetric system USP37–NF32 5031 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2: Change
(See Titrimetry <541>, Residual Titrations.)
to:
(See Titrimetry <541>.)
AND
Line 1 of Mode: Change
Direct titration
to:
Residual titration
HYDROCHLOROTHIAZIDE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3247 1-Jun-2014 USP38–NF33 USP38–NF33 Line 11 of Analysis: Change
CU = concentration of the Sample solution (μg/mL)
to:
CU = nominal concentration of hydrochlorothiazide in the Sample solution (μg/mL)
POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5350 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS
ONDANSETRON INJECTION Assay Second Supplement to USP36–NF31 Online 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36 / 329.82)(25C / V)(rU / rS)
to:
(293.36 / 329.83)(25C / V)(rU / rS)
AND
Line 8 of Procedure: Change
329.82
to:
329.83
MAGNESIUM ALUMINUM SILICATE IMPURITIES/Arsenic, Method I <211> USP36–NF31 2073 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Standard preparation: Change
Prepare as directed in the chapter.
to:
Transfer 5.0 mL (5 μg of arsenic) of the Standard Arsenic Solution to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume.
AND
Delete:
Control preparation… Read More
SODIUM ACETATE IMPURITIES/Inorganic Impurities/Potassium USP36–NF31 5147 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Sample solution: Change
Equivalent to 600 mg/mL of anhydrous sodium acetate
to:
Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water.
AND
Line 1 of Analysis: Change
To 5 mL of Sample solution add
to:
To the Sample… Read More
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS ASSAY Second Supplement to USP36–NF31 6580 1-Apr-2014 USP38–NF33 USP38–NF33 Line 2 of Procedure: Change
Inject the Sample solution within 2 h of preparation. Protect the volumetric solutions from light.
to:
Protect the volumetric solutions from light.
<81> ANTIBIOTICS—MICROBIAL ASSAYS Turbidimetric Method USP36–NF31 76 1-Apr-2014 USP38–NF33 USP38–NF33 Line 9 of Paragraph 2 of Analysis: Change
or a water bath maintained at the temperature specified in Table 8 and for the time specified in Table 11.
to:
or a water bath maintained at 36.0° –37.5° for the time specified in Table 11.
ONDANSETRON ORAL SOLUTION Related compounds USP36–NF31 4586 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36/329.82)10,000(1 / F)(1 / V)(CS / CA)(ri / rS)
to:
(293.36 / 329.83)10,000(1 / F)(1 / V)(CS / CA)(ri… Read More
ATROPINE SULFATE INJECTION ASSAY/Procedure First Supplement to USP36–NF31 5950 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Buffer: Change
Dissolve 4.1 g of sodium acetate and
to:
Dissolve 4.1 g of anhydrous sodium acetate and
<795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS COMPOUNDING FACILITIES Revision Bulletin (Official January 01, 2014) Online 1-Apr-2014 Second Supplement to USP37–NF32 Second Supplement to USP37–NF32 Line 4 of Paragraph 4: Change
(see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity;
to:
(see Packaging and Storage Requirements <659>;
CLINDAMYCIN PALMITATE HYDROCHLORIDE ASSAY/Procedure USP36–NF31 3031 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Acceptance criteria: Change
NLT 540 μg
to:
NLT 540 μg/mg
THALIDOMIDE CAPSULES Dissolution <711> USP36–NF31 5347 1-Apr-2014 USP38–NF33 USP38–NF33 After the Test solution section: Add
to:
Chromatographic system—Prepare as directed in the Assay under Thalidomide.
CALCIUM SULFATE ASSAY/Procedure First Supplement to USP36–NF31 Online 1-Apr-2014 USP38–NF33 USP38–NF33 Line 14 of Analysis: Change
Result = [(V × N × F)/W] × 100
to:
Result = [(V × M × F)/W] × 100
AND
Line 15 of Analysis: Change
V = volume of titrant consumed by the Sample (mL)
N = actual… Read More
Sodium Sulfite, Anhydrous REAGENTS/Reagent Specifications USP36–NF31 1196 1-Apr-2014 USP38–NF33 USP38–NF33 Line 2: Change
[7753-83-7]
to:
[7757-83-7]
ONDANSETRON ORAL SOLUTION Assay USP36–NF31 4586 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36/329.82)100(C/V)(rU / rS)
to:
(293.36 / 329.83)100(C / V)(rU / rS)
AND
Line 8 of Procedure: Change
329.82
to:
329.83
BUTYLPARABEN IMPURITIES/Related Substances/Chromatographic system Second Supplement to USP36–NF31 6551 1-Apr-2014 USP38–NF33 USP38–NF33 After the Column section: Add
Column temperature: 35°
<795> PHARMACEUTICAL COMPOUNDING— NONSTERILE PREPARATIONS STABILITY CRITERIA AND BEYOND-USE DATING/General Guidelines for Assigning Beyond-Use Dates Revision Bulletin (Official January 01, 2014) Online 1-Apr-2014 Second Supplement to USP37–NF32 Second Supplement to USP37–NF32 Line 7 of Paragraph 1: Change
(see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling)
to:
(see <659>)
MELPHALAN TABLETS Dissolution <711> USP36–NF31 4232 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1500:500:2:2:0.4). Make adjustments if necessary (see System Suitability under Chromatography <621>).
to:
Read More
THIMEROSAL IMPURITIES/Mercury Ions USP36–NF31 5368 1-Apr-2014 USP38–NF33 USP38–NF33 Line 19 of Analysis:
CS = concentration of mercuric chloride in the Standard solution (mg/mL)
to:
CS = concentration of mercuric chloride in Sample solution B (mg/mL)
CLARITHROMYCIN ASSAY/Procedure/System suitability USP36–NF31 3016 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Samples: Change
Standard solution 2 and Standard solution 4
to:
Standard solution 1, Standard solution 2, and Standard solution 4
AND
Line 13 of Suitability requirements: Change
Relative standard deviation: NMT 1.… Read More
RISPERIDONE TABLETS Dissolution <711> USP36–NF31 5065 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 4 of Chromatographic system: Change
Chromatograph the Standard solution and the Test solution as directed for Procedure:
to:
Chromatograph the Standard solution as directed for Procedure:
ATOMOXETINE HYDROCHLORIDE IMPURITIES/Organic Impurities, Procedure 2 First Supplement to USP36–NF31 5947 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 5 of System suitability solution: Change
dissolving the Reference Standards in ethanol,
to:
dissolving the Reference Standards in absolute alcohol,
AND
Line 2 of Sample solution: Change
dissolving it in ethanol,
to:
dissolving it in absolute alcohol,
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION CONTAMINANTS Second Supplement to USP36–NF31 6399 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Add the test:
Absence of Specified Microorganisms <2022>: Meet the requirements of the tests for the absence of Salmonella species, Escherichia coli, and Staphylococcus aureus
CANDESARTAN CILEXETIL ASSAY/Procedure USP36–NF31 2774 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Analysis: Change
Titrate with 8 mL of 0.1 N
to:
Titrate with 0.1 N
FENTANYL IMPURITIES/Organic Impurities/Acceptance criteria USP36–NF31 3554 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Footnote f of Table 2: Change
N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]acetanilide hydrochloride, or acetyl fentanyl.
to:
N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide.
VANCOMYCIN HYDROCHLORIDE FOR INJECTION SPECIFIC TESTS/Content of Vancomycin USP36–NF31 5546 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 27 of Analysis: Change
Result = [rI/(D × rB) + rA] × 100
to:
Result = {rI/[(D × rB) + rA]} × 100
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES STRENGTH/Molybdenum, Method 1 Second Supplement to USP36–NF31 6372 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of Standard solutions: Change
2.0
to:
5.0